Browse the evidence

A 20-minute documentary appealing to health, environmental, and animal welfare concerns does not reduce actual meat and animal product (MAP) consumption over a 12-day period when social desirability bias is minimized.

Watching a documentary about the benefits of reducing meat consumption is unlikely to change your actual eating habits, even if it makes you feel good about the idea. The study shows that while intentions to eat less meat may increase, actual consumption remains unchanged. To make real changes, focus on practical, small-scale adjustments to your environment and habits rather than relying on informational interventions.

Obesity lacks standardized diagnostic criteria and treatment targets compared to T2DM, leading to inconsistent care, underdiagnosis, and undertreatment.

If your doctor only uses BMI to diagnose obesity, ask for a more comprehensive assessment. This should include metabolic markers (blood pressure, lipids, glucose) and possibly the Edmonton Obesity Staging System to determine the severity of your condition and the appropriate treatment.

For individuals with obesity and prediabetes who fail to achieve early weight loss (<2.5% at 4 weeks), adding exercise counseling or time-restricted eating (TRE) counseling does not significantly improve weight loss or glycemic outcomes compared to continuing the initial diet alone.

If you are not losing weight in the first month of a diet, simply adding more exercise counseling or trying a new eating window might not be enough. You may need more intensive support, such as provided meals or supervised exercise, rather than just advice.

Changes in specific health behaviors (physical activity, diet composition, alcohol, smoking) were not consistently associated with diabetes remission in this study.

While weight loss is crucial, simply trying to change your diet or exercise habits without focusing on the resulting weight loss may not be enough to put diabetes into remission. The weight loss itself is the key factor.

GLP-1 monotherapy (liraglutide, semaglutide) is associated with high discontinuation rates due to gastrointestinal side effects, limiting long-term adherence.

Be aware that GLP-1 monotherapy can cause significant gastrointestinal side effects, leading to high discontinuation rates. Discuss titration strategies with your provider to minimize these effects.

An intensive, early post-bariatric lifestyle intervention combining nutritional-behavioral tele-counseling and supervised exercise does not improve weight loss or secondary health outcomes compared to standard care alone.

If you have had bariatric surgery, standard post-operative care is likely sufficient for optimal weight loss. Adding an intensive, early lifestyle program with frequent counseling and exercise sessions does not improve results and may be unnecessarily burdensome. Focus on sustainable habits rather than intensive early intervention.

Marketing and promotional strategies in food environments disproportionately target children with unhealthy products, with 97% of products featuring child-directed marketing falling outside healthy dietary guidelines.

Be aware that products marketed to children are overwhelmingly unhealthy. If you are a parent, expect that marketing will drive your child's requests towards these products. Limiting exposure to such marketing and choosing products without child-directed branding can help reduce the influence of these unhealthy options.

Population-level fiscal policies, such as raising cigarette prices to the EU average of $5.50, are highly cost-effective interventions that save hundreds of thousands of lives annually.

Support policies that increase the price of tobacco products. The evidence shows that higher prices directly correlate with reduced smoking rates and significant public health savings, making this a high-impact area for policy advocacy.

Obesity is significantly underdiagnosed in clinical practice, with less than half of patients with BMI ≥30 receiving a formal ICD-9 diagnosis code, creating a barrier to treatment initiation.

If you have a BMI ≥30, do not assume your provider has formally recognized your obesity. You must actively ask for the diagnosis to be documented in your chart. This formal recognition is often required to unlock insurance coverage for lifestyle interventions, medications, or specialist referrals. Without the ICD-9 code, you may be denied access to effective treatments.

Intentional weight loss is not consistently associated with reduced mortality risk and may increase mortality risk in healthy individuals.

If you are healthy and do not have obesity, intentional weight loss may not reduce your mortality risk and could potentially increase it. Instead, focus on maintaining a healthy lifestyle with regular physical activity and balanced nutrition.

In real-world commercial insurance populations without diabetes, one-year persistence on GLP-1 receptor agonists for obesity treatment is low (32.3%), with significant variation by product, contradicting high persistence rates reported in clinical trials.

If you are using a GLP-1 medication for weight loss, expect that staying on it for a full year is challenging. Real-world data shows only about 1 in 3 people stay on therapy for a year, and this varies by drug. Weekly injections (like semaglutide) tend to have better persistence than daily ones (like liraglutide). Discuss any side effects or supply issues with your doctor immediately rather than stopping abruptly, as discontinuation often leads to weight regain.

Intensive lifestyle interventions (ILI) for weight loss in type 2 diabetes require high financial investment ($2,865/year in year 1) driven primarily by personnel costs, which decreases over time as intervention intensity declines.

If you are considering a structured weight loss program for type 2 diabetes, expect to pay significantly more than self-directed efforts, especially in the first year. The cost is driven by frequent visits with dietitians and exercise specialists. However, this investment often pays off through reduced medication needs and fewer hospital visits over time. Look for programs that offer a mix of group and individual support, as these tend to be more cost-effective per person than purely individual coaching.

Real-world clinical practice fails to implement existing NAFLD guidelines, resulting in widespread underdiagnosis and suboptimal awareness.

Healthcare providers should utilize clear, simplified screening algorithms to identify at-risk patients, as current real-world implementation of guidelines is suboptimal.

Setting unrealistic initial weight loss goals (e.g., >10% or ~20% of body weight) does not negatively impact actual weight loss outcomes or treatment attrition in behavioral weight management programs.

If you have a big weight loss goal, don't stress that it's 'unrealistic' or that it will cause you to quit. The data shows that having a high goal (like 20% body weight) does not make you less likely to lose weight or drop out of a program compared to someone with a modest goal. Focus on the behavioral steps (diet/exercise) rather than worrying that your target number is too high.

A 20-minute theory-informed documentary presenting health, environmental, and animal welfare arguments does not significantly reduce actual meat and animal product (MAP) consumption over a 12-day period when social desirability bias is minimized.

Watching a documentary about the benefits of reducing meat consumption is unlikely to change your actual eating habits within two weeks, even if it makes you want to try. The study shows that while people might *say* they will eat less meat (especially if they think the researchers want them to), their actual consumption remains unchanged. To make a real change, information alone is insufficient; you need concrete plans, recipes, and environmental support, not just emotional appeals.

High cost or insurance-related barriers are the primary drivers of discontinuation for obesity pharmacotherapy with semaglutide or tirzepatide in clinical practice, accounting for nearly half of all early and late discontinuations.

If you are stopping semaglutide or tirzepatide, the most likely reason is cost or insurance issues, not that the drug didn't work. Check your insurance coverage, look for manufacturer coupons, and talk to your doctor about financial assistance programs before assuming the treatment is unsuitable for you.

Intensive dietary counseling targeting sodium reduction to <2.3 g/day fails to sustainably reduce sodium intake, blood pressure, or cardiorenal biomarkers in individuals with moderate baseline sodium intake over a two-year period.

If you currently eat a moderate amount of sodium (around 3 grams/day), trying to drastically cut it down to less than 2.3 grams through intense counseling is unlikely to work long-term. You might see a small, short-term drop in blood pressure, but it won't last, and it won't improve your heart or kidney health markers. The effort required to maintain such a low intake is likely too high for sustainable results in this group.

Adherence to liraglutide 3.0 mg for obesity treatment is extremely low (84.9% of patients exhibit low adherence), with only 15.1% achieving high adherence (PDC ≥80%) after 6 months.

If you are prescribed liraglutide 3.0 mg for weight loss, expect that most people stop taking it consistently within 6 months. High adherence (taking it daily as prescribed) is rare (15%). To succeed, you must actively manage side effects and address the burden of daily injections, possibly with dietitian support, as these are key predictors of sticking with the treatment.

Socioeconomic deprivation is strongly correlated with higher prevalence of obesity (BMI ≥40) and higher mortality rates, with the most deprived areas facing the greatest healthcare burden.

Obesity and its associated health risks are significantly higher in socioeconomically deprived areas. Public health interventions should target these areas, as they bear the greatest burden of obesity-related mortality and healthcare costs.

Intensive lifestyle intervention for weight loss in type 2 diabetes does not significantly reduce the primary composite cardiovascular endpoint (death from CV causes, nonfatal MI, nonfatal stroke, or hospitalization for angina) compared to diabetes support and education.

For people with type 2 diabetes, intensive lifestyle changes (diet and exercise) aiming for modest weight loss (7%) and activity (175 mins/week) did not statistically reduce the combined risk of heart attack, stroke, or CV death compared to standard support. However, achieving larger weight loss (10%+) and improved fitness was associated with reduced risk of CV death and major cardiac events. Continue lifestyle efforts for overall health and specific risk reduction, even if the broad 'heart attack prevention' claim is statistically unproven in this specific trial design.

Individuals with greater personal success in weight loss without medication exhibit higher obesity stigma and less favorable attitudes toward anti-obesity medications.

Healthcare providers should recognize that patients who have successfully lost weight through diet and exercise may be skeptical of or stigmatizing toward GLP-1 medications. Counseling should validate their success while explaining that biological factors can persist despite lifestyle efforts, making medication a valid and effective tool for others.

Male sex, older age (≥65 years), lower socioeconomic status (lower income, less education, higher area deprivation), and lack of insurance are associated with significantly lower odds of receiving anti-obesity medication (AOM) prescriptions and metabolic and bariatric surgery (MBS).

If you are male, older, or have limited income/insurance, you face significant systemic barriers to accessing obesity treatments like GLP-1s or surgery. This is not a reflection of your medical need but of socio-economic disparities. Seek providers who are aware of these disparities and advocate for coverage options or financial assistance programs.

Concerns about side effects, long-term health risks, and potential for weight regain are significant barriers to patient interest in incretin-based anti-obesity medications, with higher endorsement of these barriers associated with lower interest in using the therapies.

If you are considering incretin-based weight loss medications, know that your concerns about side effects, long-term risks, and weight regain are common and valid. These concerns directly impact your interest in the treatment. To overcome these barriers, engage in open discussions with your healthcare provider about the relative risks of the medication versus the risks of untreated obesity, and inquire about support for lifestyle programs designed for medication users.

Using percent body weight loss as the sole target for obesity management is not ideal because it is often not feasible or sustainable for most participants and fails to capture holistic health outcomes.

Stop fixating on a specific percentage of weight loss as the only measure of success. For many people, achieving even a modest weight loss is not sustainable. Instead, focus on patient-centered outcomes like improved blood pressure, better glycemic control, and increased quality of life, which can be achieved through various lifestyle changes regardless of the final number on the scale.